The Medicines Co (MDCO1)

Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Clive A. Meanwell
Employees:
62
8 SYLVAN WAY, PARSIPPANY, NJ 07054
973-290-6000

*** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know

The Medicines Co. is a biopharmaceutical company, which focuses on saving lives, alleviating suffering and contributing to the economics of healthcare by focusing on leading acute and intensive care hospitals worldwide. The company markets its brands Angiomax, Cleviprex, injectable emulsion, Ionsys, Kengreal, Minocin for injection, and Orbactiv. The company was founded by Clive A. Meanwell, Helmut Giersiefen, John W. Villiger and T. Scott Johnson on July 31, 1996 and is headquartered in Parsippany, NJ.

Data derived from most recent annual or quarterly report
Market Cap 6.737 Billion Shares Outstanding79.35 Million Avg 30-day Volume 3.386 Million
P/E Ratio0.0 Dividend Yield0.0 EPS-0.92
Price to Revenue0.0 Debt to Equity-31.8157 EBITDA-137.031 Million
Price to Book Value0.0 Operating Margin0.0 Enterprise Value4.599 Billion
Current Ratio0.772 EPS Growth0.114 Quick Ratio0.634
1 Yr BETA 1.2813 52-week High/Low 0.0 / Profit Margin0.0
Operating Cash Flow Growth30.7201 Altman Z-Score-0.6253 Free Cash Flow to Firm -129.071 Million
View SEC Filings from MDCO1 instead.

View recent insider trading info

Funds Holding MDCO1 (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding MDCO1 BETA

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Events (8k)

  • 8-K: filed on 2020-01-06:
    Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
  • 8-K: filed on 2020-01-06:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 2.01: Completion of Acquisition or Disposition of Assets
    Item 2.04: Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement
    Item 3.03: Material Modifications to Rights of Security Holders
    Item 5.01: Changes in Control of Registrant
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2019-11-25:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 1.01: Entry into a Material Definitive Agreement
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2019-10-30:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2019-07-24:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2019-06-28:
    Item 7.01: Regulation FD Disclosure
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2019-04-25:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2019-02-27:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2019-01-14:
    Item 8.01: Other Events
  • 8-K: filed on 2018-12-18:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
    Item 3.02: Unregistered Sales of Equity Securities
    Item 9.01: Financial Statements and Exhibits
  • Proxy

    Prospectus

    All

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    MEANWELL CLIVE CHIEF INNOVATION OFFICER

    • Officer
    • Director
    No longer subject to file 2020-01-06 0

    DENNER ALEXANDER J

    • Director
    No longer subject to file 2020-01-06 0

    GERMANO GENO J

    • Director
    No longer subject to file 2020-01-06 0

    SCHLESINGER SARAH J.

    • Director
    No longer subject to file 2020-01-06 0

    RODIN STEPHEN M EVP AND GENERAL COUNSEL

    • Officer
    No longer subject to file 2020-01-06 0

    PANAYIOTOPOULOS PARIS

    • Director
    No longer subject to file 2020-01-06 0

    VISIOLI CHRISTOPHER CHIEF FINANCIAL OFFICER

    • Officer
    No longer subject to file 2020-01-06 0

    TIMNEY MARK CHIEF EXECUTIVE OFFICER

    • Officer
    • Director
    No longer subject to file 2020-01-06 0

    WIJNGAARD PETER CHIEF DEVELOPMENT OFFICER

    • Officer
    No longer subject to file 2020-01-06 0

    KELLY JOHN C.

    • Director
    No longer subject to file 2019-09-26 0

    COX CHRISTOPHER T EVP & CHIEF CORP. DEV. OFFICER

    • Officer
    392,942 2019-03-04 0

    ESHELMAN FREDRIC N EXECUTIVE CHAIRMAN

    • Officer
    • Director
    2,076,686 2018-05-31 0

    SPIGELMAN MELVIN K

    • Director
    53,133 2018-05-25 0

    KESSLER ARMIN M

    • Director
    138,493 2018-05-10 0

    WYATT ELIZABETH H S

    • Director
    60,633 2018-03-22 0

    CROUSE WILLIAM

    • Director
    53,133 2018-03-21 0

    O'CONNOR WILLIAM BERNARD CHIEF FINANCIAL OFFICER

    • Officer
    21,882 2018-03-02 0

    FRAZIER JEFF EVP, CHIEF HUMAN STRATEGY

    • Officer
    34,350 2018-03-02 0

    HUGIN ROBERT J

    • Director
    163,431 2017-11-09 0

    SHIGETA HIROAKI

    • Director
    26,784 2017-05-25 0

    KINGSLEY STUART A PRESIDENT AND COO

    • Officer
    11,386 2017-03-01 0

    SAVAGE ROBERT G.

    • Director
    31,146 2016-05-26 0

    SBLENDORIO GLENN PRESIDENT & CFO

    • Officer
    • Director
    99,805 2015-09-03 0

    FURSE BRENT EVP, CHIEF CUSTOMER OFFICER

    • Officer
    41,044 2014-08-29 0

    KUSIAK VICTORIA EVP, CHIEF INTEGRITY OFFICER

    • Officer
    3,519 2014-03-03 0

    HEIMAN CORNELIS EVP, CHIEF INNOVATION OFFICER

    • Officer
    11,457 2014-03-03 0

    ANTINORI PAUL MICHAEL SR. VP & GENERAL COUNSEL

    • Officer
    No longer subject to file 2014-02-25 0

    ROHRBACKER LESLIE C VP, CHIEF HUMAN STRATEGY OFFIC

    • Officer
    13,628 2012-02-21 0

    FLYNN JAMES E

    DEERFIELD CAPITAL LP

    DEERFIELD PARTNERS, LP

    DEERFIELD MANAGEMENT CO /NY

    DEERFIELD INTERNATIONAL LTD

    • 10% Owner
    • POSSIBLE MEMBERS OF 10% GROUPPOSSIBLE MEMBERS OF 10% GROUPPOSSIBLE MEMBERS OF 10% GROUPPOSSIBLE MEMBERS OF 10% GROUPPOSSIBLE MEMBERS OF 10% GROUP
    No longer subject to file 2011-04-04 0

    JOHNSON T SCOTT

    • Director
    No longer subject to file 2009-07-21 0

    KELLEY JOHN P PRESIDENT AND COO

    • Officer
    • Director
    55,615 2009-02-20 0

    WATSON PACICCO KELLI SENIOR VICE PRESIDENT

    • Officer
    2,211 2009-02-20 0

    NEWBERRY CATHARINE S SENIOR VICE PRESIDENT

    • Officer
    No longer subject to file 2009-01-26 0

    KOEHLER STEVEN H SENIOR VICE PRESIDENT AND CFO

    • Officer
    3,447 2006-02-28 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed
    Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
    No current insider transactions

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin
    American Century Quantitative Equity Funds, Inc.- AC Alternatives Equity Market Neutral Fund MDCO1 -1233.0 shares, $-104731.02 2019-12-31 N-PORT
    American Century Quantitative Equity Funds, Inc.- Core Equity Plus Fund MDCO1 -8687.0 shares, $-434350.0 2019-09-30 N-PORT
    American Century Quantitative Equity Funds, Inc.- NT Core Equity Plus Fund MDCO1 -26680.0 shares, $-1334000.0 2019-09-30 N-PORT
    AQR Funds- AQR Small Cap Relaxed Constraint Equity Fund MDCO1 -257.0 shares, $-12850.0 2019-09-30 N-PORT

    Elevate your investments